WO1999046371A3 - Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery - Google Patents

Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery Download PDF

Info

Publication number
WO1999046371A3
WO1999046371A3 PCT/US1999/005359 US9905359W WO9946371A3 WO 1999046371 A3 WO1999046371 A3 WO 1999046371A3 US 9905359 W US9905359 W US 9905359W WO 9946371 A3 WO9946371 A3 WO 9946371A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptotic
induction
codelivery
cytotoxic
gene expression
Prior art date
Application number
PCT/US1999/005359
Other languages
French (fr)
Other versions
WO1999046371A2 (en
WO1999046371A9 (en
Inventor
Timothy J Mcdonnell
Stephen G Swisher
Bingliang Fang
Elizabeth M Bruckheimer
Mona G Sarkiss
Li Ji
Jack A Roth
Original Assignee
Univ Texas
Timothy J Mcdonnell
Stephen G Swisher
Bingliang Fang
Elizabeth M Bruckheimer
Mona G Sarkiss
Li Ji
Jack A Roth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Timothy J Mcdonnell, Stephen G Swisher, Bingliang Fang, Elizabeth M Bruckheimer, Mona G Sarkiss, Li Ji, Jack A Roth filed Critical Univ Texas
Priority to CA002322663A priority Critical patent/CA2322663A1/en
Priority to AU31837/99A priority patent/AU762493B2/en
Priority to EP99913854A priority patent/EP1070122A4/en
Publication of WO1999046371A2 publication Critical patent/WO1999046371A2/en
Publication of WO1999046371A9 publication Critical patent/WO1999046371A9/en
Publication of WO1999046371A3 publication Critical patent/WO1999046371A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy.
PCT/US1999/005359 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery WO1999046371A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002322663A CA2322663A1 (en) 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU31837/99A AU762493B2 (en) 1998-03-11 1999-03-11 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
EP99913854A EP1070122A4 (en) 1998-03-11 1999-03-11 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7754198P 1998-03-11 1998-03-11
US60/077,541 1998-03-11

Publications (3)

Publication Number Publication Date
WO1999046371A2 WO1999046371A2 (en) 1999-09-16
WO1999046371A9 WO1999046371A9 (en) 2000-02-17
WO1999046371A3 true WO1999046371A3 (en) 2000-08-24

Family

ID=22138678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005359 WO1999046371A2 (en) 1998-03-11 1999-03-11 Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery

Country Status (4)

Country Link
EP (1) EP1070122A4 (en)
AU (1) AU762493B2 (en)
CA (1) CA2322663A1 (en)
WO (1) WO1999046371A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110174456B (en) * 2019-06-11 2021-09-21 华润双鹤药业股份有限公司 Method for measuring lung surfactant protein and application thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266022B1 (en) * 2000-03-24 2008-10-22 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
WO2001092550A2 (en) * 2000-05-31 2001-12-06 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
AU6069601A (en) * 2000-06-02 2001-12-17 Hiroshi Okamoto Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CA2471719A1 (en) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
JP4511108B2 (en) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド Human prolactin antagonist-angiogenesis inhibitor fusion protein
CN100361710C (en) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
DE19615803A1 (en) * 1996-04-20 1997-10-23 Boehringer Ingelheim Int CELO virus
AU5817299A (en) * 1998-09-10 2000-04-03 Uab Research Foundation, The Adenoviral vector encoding pro-apoptotic bax gene and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"ONE WAY TO KILL CANCER: GIVE IT A COLD", XP002917479, Retrieved from the Internet <URL:HTTP://WWW.CNN.COM> [retrieved on 19970522] *
COLL J.L. ET AL: "Antitumor Activity of Bax and p53 Naked Gene Transfer in Lung Cancer: In Vitro and in Vivo Analysis", HUMAN GENE THERAPY, vol. 9, no. 14, 20 September 1998 (1998-09-20), pages 2063 - 2074, XP002917478 *
SAKAKURA C. ET AL: "Overexpression of Bax Sensitizes Human Breast Cancer MCF-7 Cells to Radiation-Incuced Apoptosis", INT. J. CANCER, vol. 67, 3 July 1996 (1996-07-03), pages 101 - 105, XP002917476 *
See also references of EP1070122A4 *
VOGELBAUM M.A. ET AL: "Transfection of C6 Glioma Cells with the Bax Gene and Increased Sensitivity to Treatment with Cytosine Arabinoside", JOURNAL OF NEUROSURGERY, vol. 88, no. 1, January 1998 (1998-01-01), pages 99 - 105, XP002917477 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110174456B (en) * 2019-06-11 2021-09-21 华润双鹤药业股份有限公司 Method for measuring lung surfactant protein and application thereof

Also Published As

Publication number Publication date
EP1070122A2 (en) 2001-01-24
WO1999046371A2 (en) 1999-09-16
AU762493B2 (en) 2003-06-26
EP1070122A4 (en) 2004-11-10
AU3183799A (en) 1999-09-27
CA2322663A1 (en) 1999-09-16
WO1999046371A9 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
EP1017797A4 (en) Non-primate lentiviral vectors and packaging systems
EP1315512A4 (en) Adenoviral targeting and manipulation of immune system response using targeting peptides
IL159637A0 (en) Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
WO2001022990A3 (en) Methods related to immunostimulatory nucleic acid-induced interferon
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
WO1997003635A3 (en) P16 expression constructs and their application in cancer therapy
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO1999033998A3 (en) Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof
WO1999064594A3 (en) Genes and gene expression products that are differentially regulated in prostate cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
ZA200108414B (en) Akt nucleic acids, polypeptides, and uses thereof.
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
AU3209300A (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
SI1212428T1 (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
WO2001005435A3 (en) Antisense therapy for hormone-regulated tumors
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
WO1999021589A3 (en) Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
EP1593742A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
WO2000022136A3 (en) Recombinant e1a deleted adenoviral vectors
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
CA2385872A1 (en) Gene transfer in human lymphocytes using retroviral scfv cell targeting

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE)

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
ENP Entry into the national phase

Ref document number: 2322663

Country of ref document: CA

Ref country code: CA

Ref document number: 2322663

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 31837/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999913854

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999913854

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 31837/99

Country of ref document: AU